PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38− population to imatinib

(2012) Kelly Airiau et al.   EXPERIMENTAL HEMATOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

(2010) Nathalie Carayol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells

(2009) F Belloc et al.   LEUKEMIA

mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein

(2009) Manuela Mancini et al.   LEUKEMIA RESEARCH

Nilotinib

(2008) M. W. Deininger   CLINICAL CANCER RESEARCH